Physician profile
Sameer Baig
NPI 1093129207
$3,635.63
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $459 · 2021: $379 · 2022: $224 · 2023: $206 · 2024: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $416.36 | 2019-2024 | Mounjaro, Verzenio |
| Merck Sharp & Dohme LLC | $284.52 | 2019-2024 | Keytruda |
| Pfizer INC. | $241.46 | 2019-2024 | |
| Janssen Biotech, INC. | $220.49 | 2019-2024 | Darzalex |
| E.R. Squibb & Sons, L.L.C. | $207.20 | 2019-2020 | |
| Astellas Pharma US INC | $193.60 | 2019-2020 | |
| Genzyme Corporation | $172.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $154.87 | 2019-2024 | Imfinzi |
| Amgen INC. | $125.12 | 2019-2020 | |
| Abiomed | $120.51 | 2023 | Impella |
| Celgene Corporation | $114.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.16 | 2019-2024 | Alunbrig |
| Ipsen Biopharmaceuticals, INC | $85.17 | 2023 | Tazverik |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.07 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $80.53 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.